Needle-Free Relief for Allergic Emergencies

Credit: ARS Pharmaceuticals, Inc.

The FDA recently approved Neffy, the first epinephrine nasal spray for the treatment of anaphylaxis, a potentially life-threatening condition that affects as many as 1 in 20 people in the U.S. “I am constantly seeking advancements that enhance patient safety and quality of life,” says Lauren Whalen, a certified physician assistant at Schweiger Dermatology & Allergy. “The recent approval of Neffy represents a significant milestone in the management of severe allergic reactions.” Among the most common causes of anaphylaxis are drugs and medications, foods and stinging insect allergies. Less common triggers include exercise and latex rubber allergies.

Why Go Needle-Free?

Traditionally, epinephrine has been delivered via injection, which can be intimidating for patients, especially children. “One of the most compelling features of Neffy is its ease of use,” says Whalen. “The intranasal delivery method eliminates the need for an injection, making it a less daunting option for individuals who experience anxiety about needles.”

In addition, the rapid absorption through the nasal mucosa allows for quick action, which is critical during anaphylaxis, where every second counts. This is particularly important for children, who may be more resistant to traditional epinephrine auto-injectors.

Unfortunately, Neffy is not yet approved for patients under 66 pounds. “I believe the young pediatric population would benefit most from this new technology,” she adds. “Hopefully approval is just around the corner.”

Looking Forward

The approval of Neffy has ignited the discussion about the future of allergy treatments. While it is essential to emphasize that Neffy does not replace traditional epinephrine injectors, it does provide another option that could save lives. “I appreciate that this innovation can help ensure that patients are more likely to carry their epinephrine and use it promptly when needed,” Whalen says.

“We should encourage individuals with severe allergies to consider their unique circumstances and preferences when discussing their emergency plans” she says. “As we embrace this new option, I am hopeful that it will lead to better compliance and, ultimately, better outcomes for patients facing the challenges of severe allergic reactions.”

Lauren Whalen, PA-C, is a certified physician assistant at Schweiger Dermatology Group. She has spent years training under a board-certified allergist and immunologist and has been a practicing allergy provider since 2018. Lauren treats a wide range of conditions including but not limited to food, drug and environmental allergies. She has a particular passion for pediatric food allergies and has many years of experience treating food allergies with oral immunotherapy and sublingual immunotherapy.
If you’re interested in exploring whether Neffy is appropriate for you, consult with one of Schweiger’s board-certified allergy specialists. To make an appointment, book online or call (844) 760-3380.

About Schweiger Dermatology Group

Founded by Dr. Eric Schweiger in 2010, Schweiger Dermatology Group began as a single office in Midtown Manhattan with a mission to deliver high-quality dermatologic care without long waits. As demand grew, so did the practice. Today we have over 120 locations across 8 states with more than 400 of the nation's leading providers and were ranked as the number one practice nationally in cosmetic and reconstructive care by Castle Connolly. In 2023, we broadened our expertise by integrating allergy care into our services. We remain committed to offering exceptional medical, cosmetic, and surgical dermatology as well as comprehensive allergy services, ensuring patients receive expert care in a modern, state-of-the art environment.

Back to Top